Research published in the Journal of Nuclear Medicine indicates that high-speed whole-body SPECT imaging can effectively track tumor progression in prostate cancer, enabling personalized treatment approaches. A retrospective study involving 72 patients with metastatic castration-resistant prostate cancer (mCRPC) demonstrated that imaging techniques, notably [177Lu]Lu SPECT, could provide crucial prognostic information, impacting overall survival rates. The study found that new bone lesions detected during treatment and total lesion activity (TLA) were significant predictors for patient survival. The advancements in CZT SPECT technology allow for quick imaging, improving the efficiency of monitoring treatment responses and potentially guiding adjustments in therapy for better outcomes.
Fri, 03 Oct 2025 15:15:07 GMT | Imaging Technology News